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Abstract 
 Aging is associated with the loss of appropriate immune regulation resulting in increased 
inflammatory status within the central nervous system (CNS). Microglia, the innate immune cell of 
the CNS, are particularly sensitive to age-associated dysregulation and promote an exaggerated 
inflammatory response following a peripheral or central immune challenge in aged animals. 
Recently our lab found that after a peripheral immune challenge, microglia from adult, but not 
aged, mice upregulated interleukin (IL)-4 receptor-alpha (IL-4Rα), the receptor for the anti-
inflammatory cytokine IL-4. The functional consequence of impaired IL-4Rα upregulation was 
insensitivity to the anti-inflammatory promoting effects of IL-4. Thus, to further characterize 
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potential consequences of impaired IL-4Rα upregulation on aged microglia, we conducted a series 
of studies investigating the extent to which a peripheral immune challenge with lipopolysaccharide 
(LPS) and central injection of IL-4 promoted IL-4Rα upregulation and the induction of anti-
inflammatory and neuroprotective markers in vivo. We provide evidence that upregulation of IL-
4Rα is necessary to promote a strong neurotrophin and arginase response following exposure to IL-
4. Furthermore, we show that a functional consequence of exaggerated arginase expression in 
microglia is increased polyamine production resulting in high levels of CCL2 and increased 
recruitment of macrophages to the brain. This is important because IL-4 levels are typically 
elevated in the CNS following tissue damage. Thus, impaired IL-4Rα upregulation in aged mice 
may prevent an appropriate arginase and polyamine response necessary for tissue repair and 
growth following CNS injury.  
 
Introduction 
 Aging is a normal physiological process associated with a gradual decline in immune 
regulation. Impaired immune regulation results in reduced immune function in the periphery and 
exaggerated inflammation in the central nervous system (CNS) (Dantzer et al., 2008; Corona et al., 
2012). Increased inflammation in the CNS is associated with multiple neurological complications 
including delirium, prolonged sickness, and induction of depression. Impaired regulation of 
microglia, the innate immune cell of the CNS, is likely the cause of exaggerated 
neuroinflammation in the aged brain. Microglia are long-lived cells with little to no turnover for 
the life of the animal (Ajami et al., 2007; Ginhoux et al., 2010). Thus, these cells are particularly 
susceptible to age-related increases in oxidative stress and become more inflammatory with age 
(Godbout et al., 2005; Sierra et al., 2007). Our lab and others have shown that microglia from aged 
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mice, rats, hamsters, and humans have increased markers of activation and priming (Perry et al., 
1993; Streit et al., 2004; Frank et al., 2006; Henry et al., 2009; Corona et al., 2012) associated with 
exaggerated inflammatory production after an immune challenge (Henry et al., 2009). Exaggerated 
immune activation results in increased inflammatory cytokine production and behavioral 
complications including cognitive impairment and depression-like behavior (Barrientos et al., 
2006; Chen et al., 2008; Godbout et al., 2008).  
 Microglia may become dysregulated in the aged brain, in part, from a lack of appropriate 
regulation from anti-inflammatory mediators. Fractalkine (CX3CL1), an abundant chemokine 
within the CNS, is critical in regulating a surveying and quiescent microglial state through the 
fractalkine receptor (CX3CR1) (Corona et al., 2010; Jurgens and Johnson, 2010; Bachstetter et al., 
2011). Following an immune challenge, CX3CR1 is shunted away from the membrane of microglia 
allowing for inflammatory activation. During the resolution of the inflammatory response CX3CR1 
is upregulated on the microglial cell surface even beyond baseline levels (Wynne et al., 2010). 
Microglia from aged mice, however, show extended downregulation of CX3CR1 resulting in 
prolonged inflammatory activation (Wynne et al., 2010). Confirmation that impaired CX3CR1 
upregulation results in prolonged microglial activation and induction of depression-like behavior 
was confirmed in CX3CR1 knockout (CX3CR1-/-) mice in which a peripheral injection of 
lipopolysaccharide (LPS) promoted exaggerated and extended microglial activation compared to 
their heterozygous littermates (Corona et al., 2010). 
 Recently our lab demonstrated that the receptor for interleukin (IL)-4, IL-4 receptor-alpha 
(IL-4Rα), was also impaired on microglia from aged mice. Following a peripheral injection with 
LPS, microglia from adult, but not aged, mice significantly upregulated surface expression of IL-
4Rα. The functional consequence of impaired IL-4Rα upregulation was reduced sensitivity to the 
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anti-inflammatory promoting effects of IL-4. Thus, LPS-activated microglia from aged mice had 
extended inflammatory gene expression (i.e., inducible nitric oxide synthase (iNOS)) and impaired 
upregulation of an IL-4 promoted gene (i.e., arginase) in the presence of IL-4 (Fenn et al., 2011). 
IL-4 is a classic anti-inflammatory cytokine that is primarily released by Th2-helper cells and best 
known for its promotion of antibody production in B-cells (Paul, 1991). Thus, the role of IL-4 
within the CNS is still debated. Confusion surrounding IL-4 remains, in part, because there are 
normally very low to undetectable levels of IL-4 within the CNS (Lovett-Racke et al., 2000). A 
lack of IL-4 in the CNS makes it difficult to assess the functional consequence of increased IL-4Rα 
expression on microglia. 
 We conducted a series of studies investigating the role of IL-4 administration in vivo on 
microglial activation following inflammatory activation by LPS. Here we show that a central 
injection of IL-4 one hour following a peripheral injection with LPS did not ameliorate the 
sickness response, but did reduce circulating levels of IL-6 and decrease depression-like behavior. 
Within the brain, IL-4 tended to promote a more anti-inflammatory and reparative brain 
environment with a trend towards increased M2 microglial phenotype expression. LPS, as 
expected, promoted increased inflammation and more of an M1 microglial response. IL-4 
following LPS promoted an exaggerated reparative microglial phenotype concomitant with 
exaggerated inflammatory cytokine production. Moreover, IL-4 and LPS co-treatment was 
required to induce microglial-specific arginase expression, which coincided with a significant shift 
in the brain chemokine profile resulting in increased recruitment of macrophages to the brain. 
 
Methods 
Animals  
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Adult (3-4 months old) BALB/c mice were obtained from a breeding colony kept in 
barrier-reared conditions in a specific-pathogen-free facility at the Ohio State University. Mice 
were housed in groups of 3-5 in polypropylene cages and maintained at 25° C under a 12 h 
light/12 h dark cycle with ad libitum access to water and rodent chow. At 3 months of age mice 
were individually housed under the same standard conditions until use. All procedures were in 
accordance with the National Institute of Health Guidelines for the Care and Use of Laboratory 
Animals and were approved by The Ohio State University Institutional Laboratory Animal Care 
and Use Committee. 
Experimental Protocols 
In the fist study, an indwelling cannlua was surgically implanted into the lateral ventricle 
of adult mice under ketamine anesthesia. Mice were allowed one week to recover. After one 
week mice received an intraperitoneal (ip) injection of saline or Escherichia coli 
lipopolysaccharide (LPS) (0.33 mg/kg; serotype 0127:B8, Sigma, St. Louis, MO). One hour later 
mice received an intracerebroventricular (icv) injection of vehicle or recombinant mouse IL-4 
(IL-4) (50 ng/ 2 μl; R&D, Minneapolis, MN). A subset of mice was euthanized 4 hours after LPS 
injection to evaluate plasma IL-6 levels (n=8). Another subset was assessed for sickness behavior 
using the social exploratory test 4, 8, 12, and 24 h after the LPS injection. Body mass and food 
intake were also assessed at these time-points (n=8). The final subset of mice was assessed for 
depressive-like behavior using the tail suspension test (TST) 24 h after LPS injection (n=14). 
Following the completion of the social exploratory and tail suspension tests mice were 
euthanized, blood was collected to evaluate plasma IL-6 levels, and the brain was collected. A 1 
mm coronal section from the brain was collected through the icv injection site and the remaining 
tissue was used for microglial isolation. mRNA analysis of neuroinflammatory and microglial 
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regulation genes were determined in both the brain section and microglia by real time (RT)-PCR.  
In the next study, mice underwent the same experimental procedures as above. Following 
the icv injection with IL-4, mice were left undisturbed for 23 h (24 h after LPS injection). Mice 
were then perfused with ice cold saline followed by 4 % formaldehyde. Brains were collected, 
sliced, and stained by immunohistochemistry for Iba-1, arginase, and IL-4Rα (n=4). 
In the final study, mice underwent the same experimental procedures as above. Following 
the icv injection with IL-4, mice were left undisturbed for 23 h (24 h after LPS injection). Mice 
were then euthanized and the brain was collected for microglial/macrophage isolation. 
Microglia/macrophages were stained with antibodies against CX3CR1, CCR2, CD45, and 
CD11b and analyzed by flow cytometry. Microglia were differentiated from macrophages by 
CD45 expression (microglia: CD11b+/CD45low-; macrophages: CD11b+/CD45high) (n=6). 
Intracerebroventricular cannulation surgery 
 The icv cannulation surgery was performed as previously described with a few 
modifications (Huang et al., 2008). In brief, mice were anesthetized using a mix of ketamine 
(100 mg/kg) and xylazine (10 mg/kg). The top of the head was shaved and sterilized with 
betadine and mice were positioned in a stereotaxic frame. A small incision was made on the 
cranium to expose the skull. A 26-guage stainless-steel guide cannula (Plastics One, Roanoke, 
VA) was placed in the lateral ventricle (stereotaxic coordinates from Bregma: Lat 1.2 mm; AP 
0.5 mm; Hor 2.0 mm from the dura matter). Two anchoring cranial screws were inserted adjacent 
to the cannula and the cannula was secured with cranioplastic cement (Permanent Repair Acrylic 
Powder and Liquid, Henry Schein, Inc). A dummy cannula (Plastics one, Roanoke, VA) was 
inserted in the guide cannula to prevent occlusion and infection. Mice were injected 
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subcutaneously (sc) with Buprinex (111 g/kg) following surgery and again 24 h later. Mice were 
provided a minimum of seven days to recover prior to experimental treatments. 
 For icv injections, the indwelling cannlua was connected with sterile tubing to a Hamilton 
syringe. Injections of vehicle (0.1% bovine serum albumin in saline) or IL-4 (25 ng/μl) were 
administered in a 2 μl volume (total of 50 μl IL-4) using a KS Scientific precision syringe pump.  
Behavioral Analyses 
 Social exploratory test: Mice were tested for sickness behavior using the social 
exploratory test 4, 8, 12, and 24 h after an ip injection with LPS as previously described (Huang 
et al., 2008). Briefly, a novel juvenile conspecific was introduced into the home cage of the test 
subject for 10 min. Behavior was video-taped (EthoVision XT 7.0, Noldus Information 
Technology) and the cumulative amount of time the subject mouse engaged in social 
investigation (sniffing, chasing, licking) was determined by a trained observer blind to 
experimental treatments (Bluthé et al., 1999). Baseline social behavior was determined at each 
time-point as the difference from Saline-Vehicle treated mice. Results are expressed as a percent 
decrease in time engaged in social behavior compared to the baseline measurement. 
 Tail suspension test: Mice were tested for depression-like behavior using the TST 24 h 
after LPS as previously described (Corona et al., 2010). In brief, mice were suspended by their 
tails by a piece of tape and hung in a 32 x 33 x 33 cm box for 10 min. Behavior was video taped 
(EthoVision XT 7.0, Noldus Information Technology) and the cumulative amount of time spent 
immobile was determined by a trained observer blind to experimental treatments. Results are 
expressed as total time immobile.  
Microglial/Macrophage isolation  
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Microglia and macrophages were isolated from whole brain homogenates as previously 
described (Wynne et al., 2010; Fenn et al., 2011). In brief, brains were homogenized in 
phosphate buffered saline (PBS, pH 7.4) by passing through a 70 μm nylon cell strainer. 
Resulting homogenates were centrifuged at 600 g for 6 min. Supernatants were removed and cell 
pellets were re-suspended in 70% isotonic Percoll at room temperature. A discontinuous Percoll 
density gradient was layered as follows: 70%, 50%, 35%, and 0% isotonic Percoll. The gradient 
was centrifuged for 20 minutes at 2000 g and microglia were collected from the interphase 
between the 70% and 50% Percoll layers. Microglia were washed and re-suspended in PBS. 
Each brain extraction yielded approximately 3 x 105 viable cells. We have previously 
characterized these cells as roughly 85% CD11b+/CD45low microglia (Henry et al., 2009), and 5-
10% macrophages (Wohleb et al., 2011).  
RNA isolation and qPCR 
 RNA was isolated from the 1 mm brain section of the injection site or from isolated 
microglia. For the brain section, total RNA was isolated using the Tri-Reagent protocol (Sigma, 
MO) and subjected to the DNA-free™ RNA clean up procedure (Ambion, TX). For isolated 
microglia, RNA was isolated using the PrepEase kit (USB, CA). In all RNA isolation 
procedures, RNA concentration was determined by spectrophotometry (Eppendorf, NY) and 
RNA was reverse transcribed to cDNA. 
Quantitative PCR was performed using the Applied Biosystems (Foster, CA) Taqman® 
Gene Expression assay as previously described (Godbout et al., 2005). In brief, cDNA was 
amplified by RT-PCR where a target cDNA (e.g., IL-1β, BDNF, arginase) and a reference cDNA 
(glyceraldehyde-3-phosphate dehydrogenase (GAPDH)) were amplified simultaneously using an 
oligonucleotide probe with a 5' fluorescent reporter dye (6-FAM) and a 3' quencher dye (NFQ). 
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Fluorescence was determined on an ABI PRISM 7300-sequence detection system (Applied 
Biosystems, CA). Data were analyzed using the comparative threshold cycle (Ct) method and 
results are expressed as fold difference from control. In the case of indoleamine 2,3-dioxygenase 
(IDO), results are expressed as relative units. 
Flow cytometry   
Cells were assayed for microglial cell surface antigens by flow cytometry as previously 
described (Henry et al., 2009; Fenn et al., 2011). In brief, Fc receptors were blocked with anti-
CD16/CD32 antibody. Next, enriched microglia were incubated with rat anti-mouse CX3CR1-
FITC, CD11b-PE, CD45-PerCP-Cy5.5, and CCR2-APC antibodies (eBioscience, CA). 
Expression of these surface receptors was determined using a Becton-Dickinson FACSCaliber 
four color Cytometer. Ten thousand events characterized as microglia/macrophages were 
recorded. Microglia and macrophages were identified by CD11b+/CD45low and CD11b+/CD45high 
expression, respectively (Wohleb et al., 2011). For each antibody, gating was determined based 
on appropriate negative isotype stained controls. Flow data were analyzed using FlowJo software 
(Tree Star, CA).  
Immunohistochemical Staining 
 Mice were euthanized by CO2 and immediately transcardially perfused with ice cold 
saline followed by 4% formaldehyde. Brains were collected and post-fixed in 4% formaldehyde 
for 24 h followed by 30% sucrose for another 24 h. Brains were frozen in dry-ice cooled 
isopentane and stored at -80° C until sectioned. Brains were sectioned (10 μm) using a Microm 
HM550 cryostat (Mikron Instruments) and slide-mounted. Sections of the injection site and those 
immediately adjacent were used for staining and analysis. Only animals with confirmed injection 
tracts into the lateral ventricle were used for analysis. Sections were heated for 30-45 min at 37° 
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C for antigen retrieval and blocked with 5DFTP+ (5% normal donkey serum (NDS), 0.1% fish 
gelatin, 1% bovine serum albumin (BSA), 0.1% Triton x-100). Sections were stained for goat 
anti-mouse arginase I (1:200; Santa Cruz Biotechnology) and incubated over night at 4° C. A 
flurochrome-conjugated secondary antibody (Alexa Fluor, anti-goat 546) was used for 1 h at 
room temperature. Sections were blocked for a second time with 5% NDS/1%BSA and 
incubated overnight in rabbit anti-mouse Iba-1 (1:1000; Wako Chemicals) and mouse anti-mouse 
IL-4Rα (1:100; Santa Cruz Biotechnology). Fluorochrome-conjugated secondary antibodies 
(Alexa Fluor, goat anti-rabbit 488 and goat anti-mouse 633) were then applied for 1 h at room 
temperature. Sections were cover-slipped with Fluoro-Gel (Electron-Microscopy Sciences, 
Hatfield, PA) and stored at -20° C. Images were taken with a Zeiss 510 Meta confocal 
microscope and analyzed using LSM Image Browser Zhen and Metamorph Analysis software. 
Statistical Analysis 
To ensure a normal distribution, data were subjected to the Shapiro-Wilk test using 
Statistical Analysis Systems (SAS) statistical software (Cary, NC). To determine significant 
main effects and interactions between main factors, data were analyzed using one- (i.e. 
Pretreatment and Treatment) and two- (i.e. Pretreatment x Treatment) way ANOVA using the 
General Linear Model procedures of SAS. For social exploration, data were analyzed by 
repeated measures ANOVA. When appropriate, differences between treatment means were 
evaluated by an F-protected t-test using the Least-Significant Difference procedure of SAS. All 
data are expressed as treatment means ± standard error of the mean (SEM). Values were 
considered significant at P-values < 0.05 and a tendency at P-values < 0.1. 
 
Results 
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Icv IL-4 did not ameliorate sickness behavior, but did reduce plasma IL-6 levels and depressive-
like behavior. 
 The dose of LPS selected induces a transient sickness response with mice showing 
reduced social exploratory behavior and food intake for less than 24 h (Corona et al., 2010). 
Because increased anti-inflammatory signaling in the brain (i.e., IL-10) leads to an ameliorated 
sickness response (Bluthé et al., 1999), we examined whether central injection of IL-4 would 
also improve recovery following a peripheral injection of LPS. Adult mice were injected ip with 
saline or LPS and one hour later injected icv with vehicle or IL-4. Mice were tested for social 
exploratory behavior as a measure of sickness response 4, 8, 12, and 24 h after the LPS injection. 
Body mass and food intake measurements were also collected at these time-points. As expected, 
LPS caused a significant reduction in social exploration, independent of IL-4 treatment (Main 
effect of LPS: F(1,32)=23.05, P<0.0001) (Fig.1A). Furthermore, icv IL-4 treatment did not 
reduce body mass loss or increase food intake, but rather may have potentiated these factors of 
the sickness response (Main effect of LPS: F(1,37)=137.76, P<0.0001; Main effect of IL-4: 
F(1,37)=6.76, P<0.02) (Fig.1B). 
 Our previous studies demonstrate that plasma IL-6 levels are significantly elevated 4 h 
after a peripheral LPS injection, but return close to baseline within 24 hours (Godbout et al., 
2005). We report that post-treatment with an icv injection of IL-4 prevented the LPS-induced 
increase in plasma IL-6 when assessed 4 h after the LPS injection (Fig.1C). Although there was 
not a reported interaction between LPS and IL-4 (P=0.14), Post-hoc analysis revealed that LPS-
Vehicle was significantly different (P<0.04) from all other groups, and LPS-IL-4 was not 
significantly different from Saline-Vehicle controls. 
 Because reduced IL-6 has been connected with reduced depression-like behavior 
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(Godbout et al., 2008; Howren et al., 2009), we investigated depression-like behavior 24 h after 
the LPS injection in mice treated ip with saline or LPS followed by icv vehicle or IL-4. This 
time-point was selected because social exploration behavior had returned to baseline in both LPS 
treatment groups (Fig.1A). Depression-like behavior was significantly reduced by IL-4, 
irrespective of LPS treatment (Main effect of IL-4: F(1,53)=6.37, P<0.02). These effects are 
similar to observations following treatments with anti-depressant medications (Steru et al., 
1985).  
Icv IL-4 following a peripheral injection with LPS exaggerated brain arginase and CX3CR1 
mRNA expression, and reduced IDO expression 24 h after LPS. 
 Following the findings that a central injection of IL-4 prevented the LPS-associated 
increase in plasma IL-6 with a concomitant reduction in depression-like behavior, we 
investigated the profile of mRNA expression at the IL-4 injection site in the brain 24 h after the 
LPS injection. We hypothesized that IL-4 would promote an anti-inflammatory, M2 microglial 
phenotype with the promotion of neuroprotective markers, whereas LPS would promote an 
inflammatory, M1 microglial phenotype with the reduction of neuroprotective markers. 
Furthermore, because our previous studies showed that LPS promotes IL-4Rα upregulation on 
microglia (Fenn et al., 2011), we hypothesized that many factors induced by IL-4 would be 
exaggerated by pre-treatment with LPS. To assess IL-4 responsiveness we determined the 
mRNA expression of brain derived neurotrophic factor (BDNF) (an important neurotrophin for 
neuronal health and protection), arginase (an anti-inflammatory marker associated with IL-4 
signaling), CX3CR1 (a receptor located on brain microglia important for reduced inflammatory 
activity), and indoleamine 2,3-dioxygenase (IDO) (an enzyme implicated in promoting 
depression-like behavior). 
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 Neither LPS nor IL-4 had any effect on BDNF levels 24 h after LPS injection. Arginase, 
however, was strongly induced in the Saline-IL-4 group (P<0.0003) and reduced in the LPS-
Vehicle group (P=0.06). Importantly, co-treatment with LPS and IL-4 resulted in exaggerated 
arginase expression well above levels promoted by IL-4 (LPS x IL-4 interaction: F(1,47)=4.38, 
P<0.05). From our previous studies we know that LPS treatment initially reduces CX3CR1 
expression on microglia and that by 24 h after LPS, levels return to baseline or increase slightly 
above baseline. Twenty-four hours after LPS, CX3CR1 expression in the LPS-Vehicle group was 
indeed elevated over Saline-Vehicle controls (P<0.0001) and this was further promoted in the 
LPS-IL-4 group (Tendency for LPS x IL-4 interaction: F(1,47)=2.84, P=0.1). IDO expression is 
strongly correlated with increased depression-like behavior. Nonetheless, increased depression-
like behavior in mice treated with LPS was not observed (Fig.1D). Reduced depression-like 
behavior compared to baseline, however, was observed following treatment with IL-4 
independent of pretreatment and this corresponded with reduced IDO expression in LPS-IL-4 co-
treated mice (Fig.2D).  
Icv IL-4 promoted microglial BDNF, arginase, IL-1β and IL-4Rα mRNA expression 24 h after a 
peripheral injection of LPS. 
 Previous studies by our lab and others have demonstrated that increased 
neuroinflammation and associated behavioral complications stem from activation of the innate 
immune cell of the brain, microglia (Henry et al., 2009; Corona et al., 2010; Williamson et al., 
2011; Wohleb et al., 2011). Because microglia are also important producers of BDNF and 
potentially the M2-related factor arginase, microglia from the whole brain were assessed for 
BDNF, arginase, IL-1β, and IL-4Rα mRNA expression 24 h after LPS. It is critical to point out, 
however, that a coronal brain slice of the injection site was removed prior to microglial isolation.  
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 Whereas whole brain BDNF mRNA expression was not affected by LPS or IL-4 
treatment, in microglia, BDNF levels were increased after IL-4 (Main effect of IL-4: 
F(1,35)=6.59, P<0.02). Moreover, compared to IL-4 alone (P=0.054 compared to Saline 
Vehicle), LPS and IL-4 co-treatment significantly upregulated BDNF expression (P<0.05) 
(Fig.3A).  
 Because arginase is strongly promoted by IL-4, its expression may rely heavily on the 
expression of IL-4Rα. Thus, we investigated arginase mRNA expression in microglia following 
LPS and IL-4 treatment. Indeed, Saline-IL-4 groups tended to have an increase in arginase 
expression (P=0.056). LPS-Vehicle treatment, however, significantly reduced arginase 
expression (P<0.004) (Fig.3B). These findings are consistent with the promotion of an M2 
microglial phenotype by IL-4 and an M1 phenotype by LPS (Mantovani et al., 2004; Mosser and 
Edwards, 2008). Furthermore, microglia from mice co-treated with LPS and IL-4 maintained 
high arginase expression that was significantly upregulated from Saline-Vehicle controls 
(P<0.03). Together, these data indicate a strong arginase response with IL-4 (Main effect of IL-4: 
F(1,42)=3.82, P<0.02) that may have been promoted by pretreatment with LPS. 
 Our previous study found that whereas IL-4 reduced IL-1β levels in a microglial cell line 
(BV2 cells), it had no effect on IL-1β mRNA expression in primary microglia from adult mice, 
and may have potentiated IL-1β in aged microglia (Fenn et al., 2011). Similar to these findings 
IL-4 did not reduce LPS-induced IL-1β production (Main effect of LPS: F(1,44)=14.05, 
P<0.0005), and rather significantly increased IL-1β production (LPS x IL-4 interaction: 
F(1,44)=5.40, P<0.03) (Fig.3C). Although, increased expression of IL-1β in the LPS-IL-4 group 
did not coincide with exaggerated or prolonged sickness behavior in these mice (Fig.1A). 
 IL-4Rα is a factor that was previously characterized as an M2c, or strictly anti-
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inflammatory, factor upregulated on classically deactivated microglia. Our lab and others have 
published that immune challenges including LPS (Fenn et al., 2011) and traumatic CNS injury 
(Kigerl et al., 2009) strongly promote microglial IL-4Rα surface expression. Whether this is to 
induce a negative feed-back loop to promote the return of microglia to a surveying and quiescent 
state, or whether this is a marker of increased microglial activation, are unknown. Four h after 
LPS, both LPS treated groups had increased IL-4Rα mRNA expression (Main effect of LPS: 
F(1,32)=10.14, P<0.004; data not shown). Nonetheless, 24 h after an LPS injection the only 
group that maintained elevated levels of IL-4Rα expression was the LPS-IL-4 group (LPS x IL-4 
interaction: F(1,44)=4.49, P<0.05) (Fig.3D). Elevated IL-4Rα expression on LPS-IL-4 treated 
microglia corresponded to maintained IL-1β upregulation in addition to increased markers of 
tissue repair (arginase) and neuroprotection (BDNF) in this group. 
Icv IL-4 following a peripheral injection of LPS strongly promotes arginase expression 
exclusively in microglia. 
 Although microglial expression of arginase tended to increase following co-treatment 
with LPS and IL-4, it was not to the levels found in the brain section. Thus, to determine the cell-
type responsible for the exaggerated arginase expression, mice were perfused 24 h after LPS and 
the brain was sectioned and stained for Iba-1 (microglia), arginase, and IL-4Rα. Sections at the 
injection site and immediately adjacent to the injection site were used. Arginase positive cells 
were almost exclusively Iba-1 positive indicating that arginase expression was restricted to 
microglia (Fig.4A). Furthermore, whereas arginase was slightly promoted by icv injection of IL-
4 alone (P=0.12), it was markedly induced following co-treatment with both LPS and IL-4 (LPS 
x IL-4 interaction: F(1,14)=23.72, P<0.0005) (Fig.4B). Exaggerated arginase expression was 
likely a result of elevated IL-4Rα expression following LPS treatment (Fig.4B). Although we 
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could not confirm exaggerated IL-4Rα expression by IHC, this was likely because of the high 
levels of background staining produced by the antibody. When sections adjacent to the injection 
site were evaluated, microglia positive for arginase were only noted around the ventricles and 
only in LPS-IL-4 treated mice (Fig. 4C).  
Icv IL-4 following a peripheral injection of LPS promotes the polyamine pathway important for 
chemokine production and macrophage recruitment to the CNS. 
 Despite the well characterized roles of arginase in the periphery associated with the urea 
cycle and tissue repair, the role of arginase in the CNS is still unclear (Lange et al., 2004). One 
potential implication of exaggerated arginase expression in microglia is the potentiation of the 
polyamine pathway. While the role of polyamines in the CNS is also poorly understood, a recent 
paper proposed that induction of microglial CCL2 is polyamine-dependent (Puntambeckar et al., 
2010). CCL2 is an important chemokine that strongly attracts peripheral monocytes, specifically 
differentiated CCR2+ macrophages, to sites of inflammation in the CNS (Babcock et al., 2003). 
To identify whether the functional consequence of an icv IL-4 injection was to promote 
polyamine production and CCL2 upregulation, we investigated mRNA expression of another 
enzyme important in the arginase-polyamine pathway, ornithine decarboxylase (ODC). ODC 
converts the metabolic substrate of arginase, ornithine, into the first of the three primary 
polyamines, putrescine. Indeed, LPS alone induced an increase in ODC mRNA expression (Main 
effect of LPS: F(1,38)=2.06, P<0.05) (Fig.5A). Thus, a combined effect of exaggerated arginase 
production by LPS-IL-4 co-treatment and upregulated ODC following LPS treatment could 
markedly promote polyamine production.  
 To assess the effects of increased polyamine production we evaluated mRNA expression 
of CCL2 and another chemokine important for macrophage extravasation into the CNS, 
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CX3CL1. Saline-IL-4 treatment promoted a decrease in CCL2 production compared to Saline-
Vehicle controls 24 h after saline/LPS injection (P=0.10). Furthermore, while LPS-Vehicle did 
not significantly increase CCL2 24 h after injection, LPS-IL-4 treatment significantly elevated 
CCL2 expression above all other groups (LPS x IL-4 interaction: F(1,44)=10.10, P<0.003) 
(Fig.5B). Increased CCL2 production supports an arginase-dependent exaggeration in polyamine 
production in the CNS following LPS and IL-4 co-treatment. Induction of polyamines may also 
promote a chemokine profile shift in the CNS. In concert with increased CCL2 production, LPS-
IL-4 treated mice had a significant reduction in CX3CL1 expression compared to Saline-Vehicle 
mice (P<0.005) (Fig.5C).  
 To evaluate how these shifted chemokine profiles influenced macrophage association 
with the brain, microglia/macrophages were isolated from whole brain tissue of mice injected ip 
with saline or LPS and icv with vehicle or IL-4, 24 h after the LPS injection. Corresponding with 
an increase in CCL2 expression in the brain of LPS-IL-4 mice, co-treatment with LPS and IL-4 
promoted increased accumulation of macrophages with the brain (LPS x IL-4 interaction: 
F(1,30)=3.67, P=0.067) (Fig.5D,E). 
 
Discussion 
 Microglia from adult, but not aged, mice markedly upregulate surface expression of IL-
4Rα following a peripheral immune challenge (Fenn et al., 2011). To establish the functional 
consequence of impaired IL-4Rα upregulation, we injected mice ip with saline or LPS and, one 
hour later, injected mice icv with vehicle or IL-4. We demonstrate that upregulation of IL-4Rα is 
necessary to induce an appropriate response to elevated levels of IL-4 in the brain, but does not 
impact the progression of microglial activation relating to the sickness response. For example, 
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central IL-4 did not ameliorate sickness behavior corresponding to maintained and elevated IL-
1β expression, but did reduce levels of circulating IL-6 and depression-like behavior. In the 
brain, arginase expression was markedly induced only in mice that received both LPS and IL-4 
injections and this was restricted to microglia. Increased arginase corresponded to increased 
markers of microglial regulation and neuroprotection, and reduced expression of the depression-
associated enzyme, IDO. Finally, increased arginase corresponded with polyamine-related gene 
induction (i.e., CCL2) and the recruitment of peripheral macrophages to the brain. 
 IL-4 is normally very lowly expressed or not-detectible in the adult brain (Lovett-Racke 
et al., 2000). Some studies have reported identifiable levels of IL-4 mRNA and protein within the 
hippocampus related to improved LTP, memory and learning, and neurotrophin production 
(Maher et al., 2005; Nolan et al., 2005; Lyons et al., 2007; Derecki et al., 2010). The cells 
producing IL-4 in the homeostatic brain, however, have not been identified and whether these 
results can be attributed to IL-4 remain controversial. Elevated CNS IL-4 is noted, however, after 
traumatic injury (Kim et al., 2000; Lee et al., 2010). Traumatic injury also induces high levels of 
IL-4Rα expression (Kigerl et al., 2009). The functional consequence of elevated IL-4Rα 
following an inflammatory challenge and exposure to high levels of IL-4 (mimicking a state of 
CNS trauma) is unknown. This is important because aged individuals consistently suffer 
increased morbidity and mortality following CNS trauma (Fassett et al., 2007; Anderson et al., 
2009) and this may be related to impaired IL-4Rα upregulation. 
 Icv administration of IL-4 did not improve the sickness response in mice pre-injected 
with LPS. This was not altogether surprising considering that IL-4 promoted IL-1β induction in 
LPS-treated mice. IL-1β is the primary inflammatory cytokine thought to regulate sickness 
behavior (Dantzer et al., 2008). This finding also coincided with previous work showing that a 
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simultaneous administration of central IL-4 and peripheral LPS resulted in an exaggerated 
sickness response (Bluthé et al., 2002). Thus, administration of IL-4 in the presence of 
inflammation may not promote a strict anti-inflammatory microglial phenotype. This is 
important when discussing the use of IL-4 in moderating inflammatory activation. While IL-4 in 
vitro may promote an anti-inflammatory and reparative M2a monocyte phenotype (Mantovani et 
al., 2004), the alternative activation profile promoted by IL-4 in the presence of ongoing 
inflammation may exaggerate some inflammatory cytokines leading to exacerbated tissue 
damage.  
 Icv injection of IL-4, however, did lead to reduced levels of IL-6 in the plasma 
corresponding to reduced depression-like behavior. This may have resulted from reduced IDO 
expression from microglia. IDO is an important enzyme responsible for restricting extracellular 
tryptophan levels and diverting them to sources unavailable for infiltrating pathogens. In the 
brain the role of IDO is less clearly defined and may actually divert tryptophan away from 
important neurotransmitters, including serotonin, and promote the creation of neuroactive 
metabolites responsible for increased oxidative stress and depression-like behavior (Dantzer et 
al., 2008; O'Connor et al., 2008; Haroon et al., 2012). Restricting activation of IDO promotes 
increased microglial regulation, reduced neuroinflammation, and ameliorates depression-like 
behavior (unpublished findings; (O'Connor et al., 2008)). IL-4 has been shown to reduce IDO in 
the peripheral monocytes (Musso et al., 1994), but a novel role for IL-4 in the CNS may be 
reducing damaging levels of IDO and restricting the development of depression-like behavior.  
 Other microglial regulatory factors that were upregulated by co-treatment with LPS and 
IL-4 were CX3CR1 and IL-4Rα. As expected, CX3CR1 was increased over baseline in LPS-
Vehicle mice 24 h following the LPS injection, but was further increased in LPS-IL-4 mice. 
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Exaggerated CX3CR1 in the brains of LPS-IL-4 mice appeared a sign of increased microglial 
regulation rather than merely a compensatory mechanism, as CX3CR1 levels 4 h after LPS were 
not different between LPS-Vehicle and LPS-IL-4 groups (data not shown).  
 Although BDNF levels were not changed in a gross brain section at the site of IL-4 
injection, IL-4 did promote increased BDNF expression in microglia. Microglial-specific BDNF 
expression is particularly important in the context of synaptic plasticity. Microglia are intimately 
associated with neuronal synapses and involved with synaptic pruning (Tremblay et al., 2011). 
Increased BDNF specifically in microglia could promote improved synaptic function which 
coincides with a role for IL-4 in LTP and memory and learning (Maher et al., 2005; Derecki et 
al., 2010).  
 The most significant change noted in microglia and the brain following co-treatment with 
LPS and IL-4 was a marked upregulation of arginase mRNA and protein expression. Because 
significant increases in arginase expression were only noted in microglia from LPS-IL-4 mice, 
LPS-associated IL-4Rα upregulation is likely necessary to initiate an IL-4 dependent arginase 
response in the CNS. The role of arginase in the CNS is still not well defined. While some have 
used arginase to identify “alternative activated” microglia and macrophages implicated in tissue 
repair (Gordon, 2003; Schwartz, 2003), others have focused on the ability of arginase to inhibit 
iNOS activity (Lange et al., 2004), while others have focused on the role of arginase in 
overcoming axonal growth inhibition (Cai et al., 2002). In particular, the groups focusing on 
axonal growth inhibition have identified the functional role of arginase is to produce polyamines. 
Arginase is the rate-limiting enzyme for the conversion of L-arginine to the polyamines, 
putrescine, spermidine, and spermine. The pathway includes the conversion of L-arginine to 
ornithine and urea by arginase, and the subsequent metabolism of ornithine to putrescine by 
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ornithine decarboxylase (ODC) (Soulet and Rivest, 2003). In addition to their potential roles in 
regulating axonal growth and neuronal health, polyamines may also be important for the 
regulation of chemokine profiles in the CNS (Puntambekar et al., 2011). In particular, CCL2 was 
found to be polyamine-dependent. This is important because CCL2 is the primary chemokine for 
recruiting peripheral macrophages to the CNS (Babcock et al., 2003). To confirm an increase in 
the polyamine pathway we investigated ODC mRNA expression following LPS and IL-4 
treatments. ODC was increased in both LPS-treated groups, irrespective of IL-4 treatment. This 
corresponds with previous research demonstrating increased ODC in the brain following 
inflammatory stimuli (Soulet and Rivest, 2003; Puntambekar et al., 2011). Thus, following LPS 
and IL-4 co-treatment, both arginase and ODC are upregulated and likely promote a strong 
polyamine response. Indeed when we investigated mRNA levels of CCL2 in the brain, only LPS-
IL-4 mice had significant increases in CCL2 levels. In fact, IL-4 alone decreased CCL2 levels 
demonstrating that IL-4 exposure in the presence of inflammation promotes a separate microglial 
phenotype than when exposed to IL-4 alone.  
 To identify whether increased CCL2 levels promoted increased macrophage association 
with the brain we isolated microglia/macrophages from the brain and evaluated these cells using 
flow cytometry. Microglia and macrophages were differentiated based on CD45 expression with 
microglia being CD11b+/CD45low and macrophages being CD11b+/CD45high. Corresponding 
with significantly elevated CCL2, LPS-IL-4 mice had significantly increases in the number of 
macrophages associated with the brain. To evaluate whether other major brain chemokines were 
altered by IL-4 and LPS treatment, we examined mRNA levels of CX3CL1. CX3CL1 is not only 
an important chemokine for microglial regulation, but is also thought to be important for 
perivascular macrophage extravasation into the CNS (Geissmann et al., 2003; Prinz and Priller, 
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2010). Interestingly, CX3CL1 levels were significantly reduced in the brains of LPS-IL-4 treated 
mice. First, this finding may be responsible for the exaggerated induction of CX3CR1 in this 
group observed earlier, and second, this may be important for the phenotype of the recruited 
macrophages. A recent study identified that CX3CR1-/- mice had improved tissue sparing and 
increased functional recovery following a spinal cord injury compared to heterozygous litter 
mates (Donnelly et al., 2011). Furthermore, improved recovery was associated with increased 
recruitment of CCR2+ macrophages to the site of injury. This study identified that CX3CR1+ 
macrophages were iNOS+ and increased tissue damage whereas CCR2+ macrophages were 
iNOS- associated with increased tissues repair. Thus, an increase in CCL2 and decrease in 
CX3CL1 may promote the recruitment of a specific subset of macrophages to the CNS important 
for tissue repair. 
 Together these results have implications for CNS trauma in which both IL-4 and IL-4Rα 
expression is increased in the presence of marked neuroinflammation. Because LPS-IL-4 co-
treatment strongly promoted BDNF, arginase, and CCL2 expression, inflammatory-induced 
upregulation of IL-4Rα may be necessary to mount appropriate tissue repair processes in 
response to IL-4 in the CNS. Thus, a failure to upregulate IL-4Rα on microglia of aged mice may 
result in reduced sensitivity to IL-4 following CNS trauma. Reduced sensitivity to IL-4 could 
result in impaired upregulation of neurotrophins, reduced arginase expression, and increased 
recruitment of more inflammatory, CX3CR1+ macrophages to the CNS. Moreover, because 
polyamines are also implicated in bypassing axonal growth inhibition, impaired IL-4Rα on aged 
microglia may promote increased axonal dieback and worsened functional outcome after CNS 
trauma.  
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Figure Legends 
Figure 1. Icv IL-4 reduced plasma IL-6 levels and depressive-like behavior independent of 
sickness behavior. Mice received an ip injection of saline or LPS followed by an icv injection of 
vehicle or IL-4 one hour later. A) Social exploratory behavior was evaluated prior to the 
peripheral injection and 4, 8, 12, and 24 hours after LPS and B) total body mass loss and food 
intake over the 24-hour period is reported (n=8). C) A subset of mice was euthanized at 4 and 24 
h after LPS to collect blood and evaluate plasma levels of IL-6 by ELISA (n=8-12). D) A final 
subset of mice was tested for depression-like behavior 24 h after LPS using the tail suspension 
test (TST) (n=14). Bars represent the mean ± SEM. Asterisks indicate significant difference 
(P<0.05) compared to Saline-Vehicle controls. Asterisks with a line under them (1A) denote 
significance (P<0.05) of both LPS-treated groups compared to Saline-Vehicle controls. Means 
with different letters (a,b,c) are significantly different (P<0.05) from each other.  
Figure 2. Co-treatment with LPS and IL-4 promoted exaggerated arginase and CX3CR1 
expression and reduced IDO expression. Mice received an ip injection of saline or LPS followed 
by an icv injection of vehicle or IL-4 one hour later. Following the behavioral tests shown in 
Figure 1, mice were euthanized and a brain slice at the site of IL-4 injection was collected for 
mRNA analysis (n=8). mRNA expression levels of A) BDNF, B) arginase, C) CX3CR1, and D) 
IDO are reported. Bars represent the mean ± SEM. Means with different letters (a,b,c) are 
significantly different (P<0.05) from each other. N.d. values are not-determined.  
Figure 3. Co-treatment with LPS and IL-4 promoted increased BDNF, arginase, IL-1β, and IL-
4Rα expression. Mice received an ip injection of saline or LPS followed by an icv injection of 
vehicle or IL-4 one hour later. Following the behavioral tests shown in Figure 1, mice were 
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euthanized and microglia were isolated for mRNA analysis (n=9-11). mRNA expression levels 
of A) BDNF, B) arginase, C) IL-1β, and D) IL-4Rα are reported. Bars represent the mean ± 
SEM. Means with different letters (a,b,c) are significantly different (P<0.05) from each other. 
Figure 4. Co-treatment with LPS and IL-4 promoted arginase protein expression exclusively in 
microglia. Mice received an ip injection of saline or LPS followed by an icv injection of vehicle 
or IL-4 one hour later. After 24 h mice were trancardially perfused and brains were fixed, 
sectioned, and stained for Iba-1 to denote microglia, arginase, and IL-4Rα (n=4). A) 
Representative images from the site of icv injection for Iba-1, arginase, IL-4Rα and co-labeled 
staining (20x). Single cells are enlarged images of microglia indicated by arrow. B) 
Quantification of the percent of microglia that were arginase positive and triple positive for Iba-
1, arginase, and IL-4Rα evaluated by DIA using Metamorph software. C) Representative images 
from the lateral ventricle in sections adjacent to the injection site for Iba-1, arginase, and co-
labeled staining. Single cells are enlarged images of microglia indicated by arrow. Bars represent 
the mean ± SEM. Means with different letters (a,b) are significantly different (P<0.05) from each 
other. 
Figure 5. LPS increased brain ODC expression, and co-treatment with LPS and IL-4 increased 
CCL2 mRNA and lowered CX3CL1 mRNA expression with increased association of 
macrophages with the brain. Mice received an ip injection of saline or LPS followed by an icv 
injection of vehicle or IL-4 one hour later. After 24 h mice were euthanized and 
microglia/macrophages were isolated from whole brain tissue and used for flow cytometry 
analysis of macrophage number. A) ODC, B) CCL2, and C) CX3CR1 mRNA expression in the 
brain were evaluated from mRNA collected from previous studies (Figure. 2) (n=8). D) 
Representative dot plot showing the characterization of macrophages (CD11b+/CD45high). E) 
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Quantification of the percent of macrophages associated with the brain (n=6). Bars represent the 
mean ± SEM. Means with different letters (a,b,c) are significantly different (P<0.05) from each 
other. 
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